Clinical trial
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study…
NCT00457418 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00457418 |
|---|---|
| Title | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) |
| Official title | A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | PEG-Intron |
| Enrollment | 32 |
| Start date | Feb 20, 2007 |
| Primary completion | May 27, 2008 |
| Completion | Jul 11, 2012 |
| First posted | Apr 6, 2007 |
| Last update posted | Jun 7, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: